SAKK - Young oncologist academy — Was junge Onkologen von ESMO - EHA und ESTRO berichten
Highlights in CLL
This phase 3 trial enrolled 432 patients with previously untreated CLL and coexisting medical conditions. The patients were randomized 1:1 to receive either venetoclax plus obinutuzumab or chlorambucil combined with the same obinutuzumab regimen.